IP Library Granted Patent US 10,041,074
Granted Patent B2
US 10,041,074 · App. 14/700,269 · Granted Aug 7, 2018

Euchromatic region targeting methods for modulating gene expression

Inventor: Fatih Ozsolak (Boston, MA)
Assignee: Translate Bio MA, Inc.
C12N15/1137C12N2310/11C12N2310/321C12N2310/3231C12N2320/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,041,074
App. No.
14/700,269
Granted
Aug 7, 2018
Kind
B2
Abstract

Provided herein are oligonucleotides complementary to euchromatic regions of target genes that are useful for increasing expression of the target genes; related compositions and methods are also provided.

Claims (22)

1. A method for increasing expression of a target gene in a cell, the method comprising:

(a) determining that the target gene has a euchromatic region that is a DNase I hypersensitive site of up to 1000 bp in length that overlaps an intronic or 3′ UTR sequence of the target gene, in which the antisense strand of the target gene comprises a target nucleotide sequence that i) encodes at least a portion of an RNA transcript and ii) is present within the euchromatic region;

(b) following step (a), producing an oligonucleotide of 10 to 50 nucleotides in length that has a region of complementarity that is complementary with at least 5 contiguous nucleotides in the target nucleotide sequence, wherein the region of complementarity is of sufficient length to hybridize to the RNA transcript under physiological conditions and wherein the oligonucleotide is a mixmer that does not promote cleavage of the RNA transcript by RNase H in the cell; and

(c) contacting the cell with the oligonucleotide produced in (b), thereby increasing expression of the target gene in the cell.

2. The method of claim 1 , wherein the at least 5 contiguous nucleotides in the euchromatic region are on the antisense strand of the target gene.

3. The method of claim 1 , wherein the RNA transcript is a long non-coding RNA.

4. The method of claim 1 , further comprising determining that the euchromatic region of the target gene is enriched in lysine 4 methylated histone H3 or H4 compared to an appropriate control.

5. The method of claim 1 , further comprising determining that the euchromatic region of the target gene is enriched in acetylated histone H3 or H4 compared to an appropriate control.

6. The method of claim 1 , wherein the oligonucleotide is a single stranded oligonucleotide.

7. The method of claim 1 , wherein the oligonucleotide comprises at least one modified intranucleoside linkage.

8. The method of claim 1 , wherein at least one nucleotide comprises a 2′ O-methyl.

9. A method for designing and evaluating an oligonucleotide, the method comprising:

(a) determining that a target gene in a cell has a euchromatic region that is a DNase I hypersensitive site of up to 1000 bp in length that overlaps an intronic or 3′ UTR sequence of the target gene, in which the antisense strand of the target gene comprises a target nucleotide sequence that i) encodes at least a portion of an RNA transcript and ii) is present within the euchromatic region;

(b) following step (a), producing an oligonucleotide of 10 to 50 nucleotides in length that has a region of complementarity that is complementary with at least 5 contiguous nucleotides in the target nucleotide sequence, wherein the region of complementarity is of sufficient length to hybridize to the RNA transcript under physiological conditions and wherein the oligonucleotide is a mixmer that does not promote cleavage of the RNA transcript by RNase H in the cell; and

(c) delivering to the cell the oligonucleotide produced in (b); and

(d) evaluating expression of the target gene in the cell in response to delivery of the oligonucleotide.

10. A method for increasing expression of a target gene in a cell, the method comprising:

contacting the cell with an oligonucleotide of 10 to 50 nucleotides in length that has a region of complementarity that is complementary with at least 5 contiguous nucleotides in a target nucleotide sequence,

wherein the target gene has a euchromatic region that is a DNase I hypersensitive site of up to 1000 bp in length that overlaps an intronic or 3′ UTR sequence of the target gene, wherein the antisense strand of the target gene comprises the target nucleotide sequence and the target nucleotide sequence i) encodes at least a portion of an RNA transcript and ii) is present within the euchromatic region, wherein the region of complementarity is of sufficient length to hybridize to the RNA transcript under physiological conditions, and wherein the oligonucleotide is a mixmer that does not promote cleavage of the RNA transcript by RNase H in the cell, thereby increasing expression of the target gene in the cell.

11. The method of claim 1 , wherein the oligonucleotide is 10 to 20 nucleotides in length.

12. The method of claim 9 , wherein the oligonucleotide is 10 to 20 nucleotides in length.

13. The method of claim 10 , wherein the oligonucleotide is 10 to 20 nucleotides in length.

Assignments (3)
CHANGE OF NAME Recorded Sep 8, 2017
From: RANA THERAPEUTICS, INC.
To: RANA DEVELOPMENT, INC.
Reel/Frame 043791/0278 →
CHANGE OF NAME Recorded Sep 8, 2017
From: RANA DEVELOPMENT, INC.
To: TRANSLATE BIO MA, INC.
Reel/Frame 043791/0295 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: OZSOLAK, FATIH
To: RANA THERAPEUTICS, INC.
Reel/Frame 038994/0966 →
Continuity (3)
Continuation PCTUS2014051265 · Aug 15, 2014
Provisional Application 61866772 · Aug 16, 2013
Related Publication 20150232858A1 · Aug 20, 2015
Cited By (5)
US 12,350,285 US 12,458,604 US 12,576,040 US 12,618,069 US 12,665,049